Rapid Itch Relief Seen with Nemolizumab - Takeaways - MDSpire

Rapid Itch Relief Seen with Nemolizumab

Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.

  • By

  • Kathryn Wighton

  • January 8, 2026

  • 3 min

Share

  • 1

    Nemolizumab significantly reduced itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis.

  • 2

    Treatment effects of nemolizumab were observed as early as day 2, with improvements increasing through the first 14 days.

  • 3

    A greater proportion of patients treated with nemolizumab achieved clinically meaningful itch relief compared to those receiving placebo.

  • 4

    Early itch response at day 2 was associated with sustained benefits at week 16, indicating potential long-term efficacy.

  • 5

    Improvements in sleep disturbance paralleled itch outcomes, suggesting enhanced quality of life for patients receiving nemolizumab.

Original Source(s)

Rapid Itch Relief Seen with Nemolizumab

  • by Kathryn Wighton

  • January 8, 2026

Related Content

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management